Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis
Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis is a paper indexed in PICO Portal from OpenAlex.
How many citations does Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis have?
Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis has 73 citations in the OpenAlex counts PICO Portal stores.
When was Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis published?
Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis has 2007 year in the PICO Portal index.
What is the open-access status of Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis?
Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis has closed oa status in the PICO Portal index.
What is the DOI of Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis?
The DOI for Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis is on the source record.
What is the PMID of Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis?
The PMID for Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis is on the source record.
What is the OpenAlex record for Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis?
The OpenAlex for Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis is on the source record.